Chengdu Kanghua Biological Products (300841) - Total Liabilities
Based on the latest financial reports, Chengdu Kanghua Biological Products (300841) has total liabilities worth CN¥430.82 Million CNY (≈ $63.04 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 300841 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Chengdu Kanghua Biological Products - Total Liabilities Trend (2015–2024)
This chart illustrates how Chengdu Kanghua Biological Products's total liabilities have evolved over time, based on quarterly financial data. See Chengdu Kanghua Biological Products (300841) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Chengdu Kanghua Biological Products Competitors by Total Liabilities
The table below lists competitors of Chengdu Kanghua Biological Products ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Huadian Power International Corporation Limited
F:SHX
|
Germany | €155.16 Billion |
|
Orient Semiconductor Electronics Ltd
TW:2329
|
Taiwan | NT$11.15 Billion |
|
Yotrio Group Co Ltd
SHE:002489
|
China | CN¥3.60 Billion |
|
Janux Therapeutics Inc
NASDAQ:JANX
|
USA | $86.69 Million |
|
Clean Science and Technology Limited
NSE:CLEAN
|
India | Rs1.84 Billion |
|
Hebei Sailhero Environmental
SHE:300137
|
China | CN¥359.97 Million |
|
AirAsia X Bhd
KLSE:5238
|
Malaysia | RM42.57 Billion |
|
Central Reinsurance Corp
TW:2851
|
Taiwan | NT$38.63 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Chengdu Kanghua Biological Products's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Chengdu Kanghua Biological Products stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chengdu Kanghua Biological Products's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chengdu Kanghua Biological Products (2015–2024)
The table below shows the annual total liabilities of Chengdu Kanghua Biological Products from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥580.07 Million ≈ $84.88 Million |
-16.56% |
| 2023-12-31 | CN¥695.22 Million ≈ $101.73 Million |
+9.41% |
| 2022-12-31 | CN¥635.40 Million ≈ $92.98 Million |
+82.72% |
| 2021-12-31 | CN¥347.74 Million ≈ $50.89 Million |
+100.72% |
| 2020-12-31 | CN¥173.24 Million ≈ $25.35 Million |
+51.32% |
| 2019-12-31 | CN¥114.49 Million ≈ $16.75 Million |
-3.29% |
| 2018-12-31 | CN¥118.37 Million ≈ $17.32 Million |
+37.05% |
| 2017-12-31 | CN¥86.38 Million ≈ $12.64 Million |
-70.94% |
| 2016-12-31 | CN¥297.23 Million ≈ $43.49 Million |
+9.03% |
| 2015-12-31 | CN¥272.61 Million ≈ $39.89 Million |
-- |
About Chengdu Kanghua Biological Products
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines. In addition, it exports its products. Chengdu Kanghua Biological Produc… Read more